

0

03 August 2017 | Opinion

**Vaccines are capable of treating infectious and non-infectious diseases rather than just prevent them. Various vaccines are being designed to treat auto-immune diseases or allergic disorders too. The vaccines are also being designed to switch-off unwanted immune response rather than induce an immune response which is also called negative vaccination. The field of vaccine research, thus, holds a bright future and will have a huge market in terms of demand.**



Considered a medical boon, vaccination is the most efficient way to prevent a disease outbreak. History has witnessed the eradication of diseases such as polio, smallpox etc. However, at present there is a growing distrust amongst the individuals regarding the safety of the vaccines. People who support anti-vaccine movement opine that there is a link between autism and Measles-Mumps-Rubella vaccine.

The anti-vaccine movement has risen in a scenario when the world is searching for ways to prevent the deadly disease outbreaks by viruses like Ebola, Zika, Influenza etc. Many pharmaceutical companies are looking at strengthening their R&D infrastructure, in order to develop vaccines for such deadly disease outbreaks. WHO also has launched an Initiative for Vaccine Research (IVR) with an aim to facilitate the development and introduction of safe, effective and affordable vaccines. A report released by the Transparency Market Research on the global foot and mouth disease (FMD) vaccines market, forecasts the growth of the overall FMD vaccines at a CAGR of 8.8% until 2020. The FMD vaccine market was valued at US \$ 0.51 billion in 2013.

The Asia Pacific Region is said to dominate the vaccines market. Novel attenuated strains of measles, mumps, hepatitis A, rotavirus and intra nasally delivered pandemic H1N1 virus have been derived for products distributed principally within the region. The demand is also because there is a large proportion of adults in Asia which is disease-prone.

Many countries in the Asia-pacific region have developed the vaccines for various disease outbreaks. Although Japan is considered as the innovator of vaccines which are used internationally, countries like China, India, Australia and Vietnam are not far behind. Bharat Biotech, a vaccine manufacturer of a developing nation India, has developed a Zika vaccine candidate. The candidate Zika vaccine developed by Bharat Biotech is inactivated virus vaccine developed using an African strain of the

virus. The vaccine when tested in mice, conferred 100% protection against infection caused by the contemporary Asian strains as well. The vaccine is now undergoing Phase 1 clinical trials in India. CPL Biologicals, another Indian company which launched world's first VLP based Influenza vaccines in India has collaborated with the clinical stage biotechnology company Novavax Inc., USA. As part of this joint venture partnership, CPL Biologicals has access to Novavax's proprietary Virus Like Particles (VLPs), recombinant nanoparticles and adjuvant technologies. CPL Biologicals is developing novel and innovative vaccines based on these technologies utilizing the Sf9/baculovirus (BV) expression platform.

"Our carefully designed genetic constructs allow us to tailor the vaccines to key components of pathogens, which we believe enhances functional immunity and leads to better protection against infection and disease. Our Sf9/BV platform efficiently expresses large antigens and particles, which in turn promote superior immunogenicity and better functional immunity. Our manufacturing platform can produce proteins that are properly folded and modified, which can be critical for functional, protective immunity. Unlike traditional vaccine manufacturing, we do not need to grow an actual virus. Our platform technology is completely recombinant, enabling us to manufacture the vaccines against highly pathogenic targets such that no infectious agents are required, there is no requirements for higher BSL facilities and, therefore, no safety threats," the company said.

The company conducts end-to-end research, development and manufacturing based on these technologies in India and in the US. It has a strong management team comprising of deep expertise and experience in the areas of Research, Process Development, Medical Affairs, Manufacturing, Commercialization etc. and is governed by the Board of Directors with representation from both Novavax and Cadila leadership.

Genocea Biosciences, a biopharmaceutical company headquartered in Cambridge, MA, have successfully developed a genital herpes vaccine. While traditional immunotherapy discovery methods have largely used predictive means to propose T cell targets, or antigens, Genocea has successfully developed AnTigen Lead Acquisition System (ATLAS™) to identify clinically relevant antigens of T cells, potentially increasing the likelihood of successful clinical development of vaccines and immunotherapies.

Gen-003 an investigational immunotherapy to treat genital herpes is made using this technology. GEN-003 was designed to elicit both a targeted T cell and B cell (antibody) immune response in patients with genital herpes. Genocea is currently finishing up its Phase 2 program on GEN-003, and recently had a successful end of Phase 2 meeting with the FDA. We expect to announce the 12-month placebo-controlled clinical results from the Phase 2b trial for the expected Phase 3 endpoint in the middle of 2017. Genocea plans to have GEN-003 ready for Phase 3 by the end of 2017.

"We expect the clinical trials to take approximately 2 years from initiation to data and could therefore be in a position to file our BLA in the U.S. in 2020, with the potential for approval in 2021. If successfully developed and marketed, GEN-003 would be the first new therapy in more than 20 years to treat the large and unsatisfied global genital herpes patient population and the first successful therapeutic vaccine targeting a chronic infectious disease," the company said.

The company is using the technology to drive the immune-oncology program which includes the lead immuno-oncology candidate GEN-009, a neoantigen cancer vaccine on which it plans to file an IND by the end of 2017, a pre-clinical vaccine candidate against Epstein-Barr Virus (EBV)-related cancers, a tumor-associated antigen (TAA)/common antigen vaccine, and non-invasive companion diagnostics to profile T cell responses in responders and non-responders to checkpoint blockade therapies with the goal of improving patient selection and outcomes for clinical practice.

When asked about the current vaccines in the pipeline to CPL Biologicals, the company said that

"Our recombinant influenza vaccines for H1N1 (Swine Flu) and Seasonal Flu offer significant advantages over the currently available conventional influenza vaccines. We will be applying for registration/marketing authorization in multiple countries outside of India for these vaccines in the coming year.

Our next vaccine to be commercialized will be a 3 dose Rabies vaccine based on the nanoparticle technology which is currently in phase III human clinical trials. CPL Biological's Rabies vaccine with a 3 dose regimen (0-3-7 days) will be a significant improvement over currently available vaccines around the globe where one needs 5 doses over a period of 28 days (0-3-7-14-28). Our vaccine will significantly improve compliance towards full course of immunization as the dropout rate for the current Rabies vaccines is maximum for doses 4 and 5 (Day 14 and 28). Our eventual target is to reduce the number of doses for the Rabies vaccine to a single dose. That will help us significantly improve the coverage and compliance

of the vaccine and save human lives across the world. Our Rabies vaccine will be the first recombinant Nano-particle based Rabies vaccine to be licensed anywhere in the world.

The next vaccine in the early stages of development is a Varicella Zoster Virus (VZV) vaccine. Currently, no VZV vaccine is manufactured in India and all of them are imported as bulk or finished formulations. This results in limited supply/shortage of the vaccine. Our VZV vaccine will be the first VZV vaccine to be completely developed and manufactured in India and will address the current shortage of this critical vaccine in the Indian market.”

The company, in addition to these, is also working on the development of Middle East Respiratory Syndrome (MERS) Nanoparticle vaccine. Its current marketed products include CadiFlu, an H1N1 pandemic influenza vaccine and Cadiflu-S, a seasonal influenza vaccine.

Despite this success, there is still a great need for new vaccines. Also, all vaccine candidates must be put through a lengthy, rigorous process of scientific evaluation before they can be licensed for general use. This process is time-consuming- it can take up to a decade just to move a candidate vaccine through the three phases of clinical development alone. But it is also indispensable. The clinical trials in which vaccines are evaluated ensure that licensed vaccines are safe, effective and appropriate for the populations most likely to use them. The company CPL Biologicals says “By volume, India is the largest manufacturer of vaccines in the world. However, most of these are supplied to governments and public health agencies across the world at very competitive prices. It is very challenging for the Indian vaccine industry to provide cost-effective vaccines with compliance to best regulatory standards like WHO and US FDA. Developing novel, high-impact vaccines is a major challenge for the Indian vaccine industry to re-invent and sustain itself in the long run. CPL Biologicals is taking a major step in that direction by developing novel vaccines based on cutting-edge technology.

Globally, adult vaccination is a proven way of improving the overall health and productivity of the society, however, it has not caught up in India due to lack of awareness and availability of options. Therefore, the market for adult vaccines is extremely limited in India. CPL Biologicals is partnering with relevant stakeholders and spreading awareness for adult vaccination in India with its Seasonal Influenza and Swine Flu vaccines.

Some of the major hurdles in developing new vaccines in India include the absence of firm epidemiological data, lack of availability of the challenge animal models/challenge facility, lack of discovery of surrogate markers of protection to newer disease agents and lack of central laboratory like CDC in USA to support discovery of disease-causing agents and providing seed vaccine strains.”

While throwing some light on the challenges faced in developing a new vaccine candidate, Sumathy K, Director, R&D, Bharat Biotech said “Developing an investigational new vaccine throws up several challenges, particularly so when the vaccine is for infectious diseases that cause epidemic outbreaks which are episodic and unpredictable in occurrence. The lack of reference reagents, reference vaccine strain, well-studied animal models for vaccine testing and rationalizing doses for clinical development in the absence of knowledge on immune correlates of protection are the major challenges faced in new vaccine development. The above points have to be adequately addressed in R&D during product development before advancing it to clinical studies.”

Genocea Biosciences while talking about its Herpes vaccine said “Simply put, we believe that other candidate genital herpes vaccines have failed because they have used the wrong antigens, and have therefore not effectively directed T cell responses to attack the virus. We selected the GEN-003 antigens using our ATLAS™ platform, which comprehensively profiled the T cell immune responses of approximately 200 people to HSV-2 and associated those T cell response signatures with clinical outcomes. We found that a handful of HSV-2 antigens were associated with protective T cell responses and, from that small number of antigen candidates, we selected the two protein components of our vaccine. We have now shown in 3 clinical trials that GEN-003 reduces the genital lesion rate, reduces viral shedding, and drives strong and antigen-specific T and B cell responses. We believe that GEN-003 addresses significant unmet medical needs of genital herpes sufferers that are not addressed by currently available oral therapies. We know from our market research that patients hate taking a pill every day and for this reason, a majority of patients who take antivirals only take them when they have a lesion recurrence (episodic use). This drives a significant unmet medical need because taking antivirals in this way does nothing to reduce the frequency of recurrences and provides no reduction in viral shedding when they are not taking the pills (increasing transmission risk). Our market research suggests that the prospect of GEN-003's significant and sustained efficacy from a single course of injections would cause many patients currently taking antivirals to switch or take GEN-003 in combination with existing therapies. You can also imagine a scenario where GEN-003 could be the cornerstone therapy for a patient, who could preserve antiviral use to treat outbreaks if they occur. We do plan to study GEN-003 in combination with daily Valtrex in the future to see if there is an additive benefit of taking both together.”

Vaccines are capable of treating infectious and non-infectious diseases rather than just preventing them. Various vaccines are being designed to treat auto-immune diseases or allergic disorders too. The vaccines are also being designed to switch-off

unwanted immune response rather than induce an immune response which is also called negative vaccination. The field of vaccine research, thus, holds a bright future and will have a huge market in terms of demand.